UroGen Pharma Ltd.
URGNUnited States
51 filed reports · 402 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
51 reports · Dec 2017 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 26 guidance figures, 143 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 23 | 3,351 | Mar 2019 to Jun 2026 |
| Current · 8-KSEC EDGAR | 13 | 26 | Dec 2018 to Mar 2026 |
| Annual · 10-KSEC EDGAR | 8 | 2,808 | Dec 2018 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 3 | 3 | Dec 2022 to Dec 2024 |
| Interim · 6-KSEC EDGAR | 3 | 196 | Mar 2018 to Sep 2018 |
| Annual · 20-FSEC EDGAR | 1 | 150 | Dec 2017 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 356 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 239 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 2, 2026 | 615 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 237 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 161 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 162 | Open |
| FY2024 | 10-K/A | Dec 31, 2024 | Apr 30, 2025 | 1 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 10, 2025 | 366 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 131 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 13, 2024 | 125 | Open |
| FY2024 Q1 | 8-K | Mar 31, 2024 | May 13, 2024 | 2 | Open |
Financial data
402 concepts · 6,534 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial391 concepts · 6,453 facts · Dec 2015 to Jul 2026
- Revenue53 · Dec 2016 to Jun 2026
- Cash and cash equivalents at carrying value51 · Dec 2015 to Jun 2026
- Stockholders equity (US GAAP)51 · Dec 2015 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value49 · Dec 2015 to Jun 2026
- Allocated share based compensation expense49 · Dec 2015 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities49 · Dec 2015 to Jun 2026
- Increase decrease in employee related liabilities49 · Dec 2015 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets49 · Dec 2015 to Jun 2026
- Net cash provided by used in financing activities49 · Dec 2015 to Jun 2026
- Net cash provided by used in investing activities49 · Dec 2015 to Jun 2026
- Net cash provided by used in operating activities49 · Dec 2015 to Jun 2026
- Net income loss49 · Dec 2015 to Jun 2026
- Operating income loss49 · Dec 2015 to Jun 2026
- Payments to acquire property plant and equipment49 · Dec 2015 to Jun 2026
- Share based compensation49 · Dec 2015 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations48 · Dec 2015 to Jun 2026
- Research and development expense47 · Mar 2017 to Jun 2026
- Accounts payable and accrued liabilities current46 · Dec 2016 to Jun 2026
- Assets46 · Dec 2016 to Jun 2026
- Assets current46 · Dec 2016 to Jun 2026
- Common stock par or stated value per share46 · Dec 2016 to Jun 2026
- Common stock shares authorized46 · Dec 2016 to Jun 2026
- Common stock shares issued46 · Dec 2016 to Jun 2026
- Common stock shares outstanding46 · Dec 2016 to Jun 2026
Product1 concepts · 40 facts · Sep 2020 to Jun 2026
- Revenue40 · Sep 2020 to Jun 2026
Guidance2 concepts · 26 facts · Feb 2019 to May 2026
- Revenue Guidance22 · Nov 2021 to May 2026
- Net Income Guidance4 · Feb 2019 to Nov 2019
Segment7 concepts · 14 facts · Jun 2025 to Jun 2026
- Acquisitions of IPR&D2 · Jun 2025 to Jun 2026
- Communications information technology and occupancy2 · Jun 2025 to Jun 2026
- Other research and development expense2 · Jun 2025 to Jun 2026
- Other selling general and administrative expense2 · Jun 2025 to Jun 2026
- Research and development expense2 · Jun 2025 to Jun 2026
- Research and development expense excluding acquired in process cost2 · Jun 2025 to Jun 2026
- Selling general and administrative expense2 · Jun 2025 to Jun 2026
Geography1 concepts · 1 facts · Dec 2020
- Operating lease impairment loss1 · Dec 2020
Segments
55 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service2 members · 40 facts
- Jelmyto30 · Sep 2020 to Jun 2026
- Zusduri10 · Sep 2024 to Jun 2026
Statement business segments1 member · 14 facts
- Single Reportable14 · Jun 2025 to Jun 2026
Statement geographical1 member · 1 facts
- NY1 · Dec 2020
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.